FDA Evaluates Safety and Cost of Gene Therapy for Sickle Cell Disease

Gene therapies for sickle cell disease are being considered for approval by the FDA, offering hope for patients like Myles Newsome who suffer from the debilitating blood disorder. These therapies have shown promising results in clinical trials, with some patients experiencing a complete cure. However, there are risks involved, including potential long-term effects and high costs. If approved, gene therapy could provide a chance for thousands of sickle cell patients to improve their quality of life and potentially avoid further organ damage and premature death. The decision by the FDA is expected by December 8th.